SCHEMBL78286

SCHEMBL78286

Oc1c(F)cc(F)cc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.56
CA9 Q16790 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
IDO1 P14902 1/20 0.45
NOTUM Q6P988 1/20 0.43
CES2 O00748 3/20 0.42
CES1 P23141 3/20 0.42
CA3 P07451 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
VRK1 Q99986 2/20 0.37
RPS6KA3 P51812 1/20 0.36
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27540052 0.97 ERN1 (0.54) ERN1CA9CA12CA1IDO1
SCHEMBL5513552 0.87 ERN1 (0.52) ERN1CA9CA12CA1IDO1
SCHEMBL8059874 0.84 IDO1 (0.55) ERN1CA9CA12CA1IDO1
Trifluoroacetic Acid SCHEMBL30390569 0.80 ERN1 (0.52) ERN1CA9CA12CA1IDO1
SCHEMBL5315670 0.80 ERN1 (0.46) ERN1CA9CA12CA1IDO1
SCHEMBL104581 0.80 ERN1 (0.46) ERN1CA9CA12CA1IDO1
SCHEMBL815794 0.80 ERN1 (0.46) ERN1CA9CA12CA1IDO1
SCHEMBL1521925 0.80 ERN1 (0.46) ERN1CA9CA12CA1IDO1
SCHEMBL1155741 0.80 ERN1 (0.46) ERN1CA9CA12CA1IDO1
SCHEMBL5399616 0.80 ERN1 (0.46) ERN1CA9CA12CA1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 913 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149479-A1 SYNTHESIS OF MODIFIED NUCLEOSIDE TRIPHOSPHATES ROCHE DIAGNOSTICS GMBH (DE) 2025-07-17 WO claimed
US-11485806-B2 Process for the preparation of polymerized polyethylene wax SCG CHEMICALS CO., LTD. (TH) 2022-11-01 US claimed
CN-113214623-A Preparation method of phosphorus-halogen synergistic flame-retardant unsaturated polyester resin material 中国科学技术大学 2021-08-06 CN claimed
EP-3318544-B1 PROCESS FOR THE PREPARATION OF POLYMERIZED POLYETHYLENE WAX SCG CHEMICALS CO LTD (TH) 2020-03-18 EP claimed
US-20190263947-A1 PROCESS FOR THE PREPARATION OF POLYMERIZED POLYETHYLENE WAX SCG CHEMICALS CO., LTD. (TH) 2019-08-29 US claimed
EP-3318544-A1 PROCESS FOR THE PREPARATION OF POLYMERIZED POLYETHYLENE WAX Scg Chemicals Co. Ltd. (TH) 2018-05-09 EP claimed
CN-102809559-B Method for detecting halogenated aromatic organic matter RES CT ECO ENVIRONMENTAL SCIEN 2015-06-17 CN claimed
US-20140288249-A1 Methods for Producing Polyolefins With Catalyst Systems UNIVATION TECHNOLOGIES, LLC (US) 2014-09-25 US claimed
EP-2776476-A1 METHODS FOR PRODUCING POLYOLEFINS WITH CATALYST SYSTEMS Univation Technologies, LLC (US) 2014-09-17 EP claimed
WO-2013070602-A1 METHODS FOR PRODUCING POLYOLEFINS WITH CATALYST SYSTEMS UNIVATION TECHNOLOGIES, LLC (US) 2013-05-16 WO claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
EP-1066269-B1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2005-05-11 EP claimed
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives DAEYAERT FREDERIK FRANS DESIRE (BE) 2002-08-22 US claimed
US-6333388-B1 Aluminum compound-containing solid catalyst component, catalyst for olefin polymerization and method for producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-12-25 US claimed
EP-1066269-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-10 EP claimed
US-6150360-A ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE JANSSEN PHARMACEUTICA N.V. (BE) 2000-11-21 US claimed
US-6100213-A Aluminum compound-containing solid catalyst component, catalyst for olefin polymerization and method for producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-08-08 US claimed
WO-1999050256-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 1999-10-07 WO claimed
WO-1996012723-A1 PROCESS FOR PREPARING ALKYLSILYL OR ARYLSILYL ETHERS FMC CORPORATION (US) 1996-05-02 WO claimed
US-5493044-A Process for preparing alkylsilyl or arylsilyl ethers FMC CORPORATION (US) 1996-02-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives XDH, CCR5, CXCR1 ERN1 703/4885CA9 4825/4885CA12 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.